
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is poised for success as they have a strong pipeline and a proprietary, in-house cell-based manufacturing platform that sets them apart from competitors. The company has reported positive revenue growth and net income for the fourth quarter of 2025, and has a strategic roadmap for 2026 that focuses on advancing their platform across multiple diseases. Management's focus on expanding their pipeline through both internal development and strategic partnerships further adds to the company's potential for growth and success.
Bears say
Lineage Cell Therapeutics is facing multiple risks including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. While the company has shown progress in its partnership with Roche and Genentech and advancements in its AlloSCOPE platform, its limited cash reserves and potential competition in the market for its therapies raise concerns about its ability to sustain its operations and gain market share. Additionally, the company's focus on degenerative diseases, while important, may limit its potential for diversification and growth in the increasingly competitive biotechnology industry.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares